

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

 Migraine is a highly prevalent neurovascular disorder for which genome-wide association studies (GWAS) have identified over one hundred risk loci, yet the causal variants and genes remain mostly unknown. Here, we meta-analyzed three migraine GWAS including 98,374 cases and 869,160 controls and identified 122 independent risk loci of which 35 were new. Fine-mapping of a meta-analysis is challenging because some variants may be missing from some participating studies and accurate linkage disequilibrium (LD) information of the variants is often not available. Here, using the exact in-sample LD, we first investigated which statistics could reliably capture the quality of fine-mapping when only reference LD was available. We observed that the posterior expected number of causal variants best distinguished between the high- and low-quality results. Next, we performed fine- mapping for 102 autosomal risk regions using FINEMAP. We produced high-quality fine-mapping for 93 regions and defined 181 distinct credible sets. Among the high- quality credible sets were 7 variants with very high posterior inclusion probability (PIP > 0.9) and 2 missense variants with PIP > 0.5 (rs6330 in *NGF* and rs1133400 in *INPP5A*). For 35 association signals, we managed to narrow down the set of potential risk variants to at most 5 variants.

-
-

Introduction

 Migraine is a common neurological disorder characterized by recurrent disabling episodes of severe headache that are typically one-sided, pulsating in nature, and

 accompanied by other symptoms such as nausea, and hypersensitivity to light and/or sound. It has two main subtypes, migraine without aura and migraine with aura. The aura is a reversible visual, sensory or speech disturbance, that typically occurs before the headache phase. Migraine attacks last usually from 4 to 72 hours, 49 and can significantly harm daily life of patients¹. Migraine was ranked as the second most disabling disease worldwide in terms of years lived with disability by Global 51 Burden of Diseases Study in 2019². Its lifetime prevalence has been estimated to be about 15 to 20 % worldwide, and it is three times more common in females than in 53 males². Family and twin studies estimate the heritability to be about 40% ³. To date, 54 over 100 migraine associated loci have been reported by GWAS^{4,5,6,7,8,9,10,11,12,13,14}. The genetic association of migraine has shown a general enrichment in genes highly 56 expressed in vascular and central nervous system related tissues^{15,13} but we lack detailed information on specific genetic variants that affect the migraine risk.

 Identification of causal genes and variants that have a biological effect on migraine is crucial for understanding the biology of migraine, and for developing new effective treatments for the disorder. Here, we aim to narrow down correlated genetic variation in migraine associated regions to a smaller number of candidate causal variants by 63 applying statistical fine-mapping¹⁶. Fine-mapping methods evaluate how plausibly each variant in the region is among the causal variants by utilizing the observed 65 association statistics and the LD structure of the region¹⁶. Multiple methods that can 66 utilize GWAS summary statistics have been developed, including PAINTOR¹⁷, 67 CAVIAR¹⁸, FINEMAP¹⁹, JAM²⁰ and SuSIE²¹. The optimal way to apply fine-mapping is to compute the LD information from the original GWAS data (in-sample LD), but when the original genotype data are unavailable, approximate LD information is often

 obtained from a reference genotype panel (reference LD). However, when reference LD is used, the discrepancy from the in-sample LD can cause errors in fine-mapping and this problem becomes more severe as the GWAS sample size grows²².

 Even though large meta-analyses have become a successful way to increase statistical power of GWAS, they remain difficult to fine-map reliably for several reasons²³. First, meta-analyses are combinations of multiple studies and typically no single analyst has access to the exact in-sample LD of the whole meta-analysis, which means that reference LD must be used. Second, differences in genotyping platforms and genotype imputation pipelines between the meta-analyzed studies can bias the fine-mapping results. Third, some variants included in the meta-analysis may be present in only a subset of the studies, which leads to variation in information content of the association statistics of different variants. In a landmark fine-mapping study on schizophrenia, Trubetskoy et al. $(2022)^{24}$ avoided these problems by collecting all genotype-phenotype data into a single analysis site. Unfortunately, to our knowledge, no other international disease consortium has been able to create a comparable analysis environment that would allow an in-sample fine-mapping of a large meta-analysis. Given that fine-mapping of meta-analysis results typically relies on reference LD, a crucial question is how we can assess when the results of fine-mapping based on reference LD are reliable.

 So far, the largest GWAS meta-analysis on migraine contained 102,084 cases and $-771,257$ controls from 25 study collections¹³. Unfortunately, we cannot perform reliable fine-mapping for that meta-analysis, since the in-sample LD is not available. Instead, we conducted a migraine meta-analysis with 98,374 migraine cases and

 869,160 controls by combining data from three sources: 23andMe, Inc., FinnGen, and UK Biobank (UKB). Of these data sets, 23andMe and UKB were included in the earlier meta-analysis of Hautakangas et al. (2022) while FinnGen was not. Statistical power of our meta-analysis was comparable to the previous migraine meta-analysis of Hautakangas et al. (2022), with effective sample sizes of 339,000 and 326,000, respectively. Importantly, we have the full in-sample LD available for 26 risk loci and 101 for the remaining risk loci we have the in-sample LD for FinnGen and UKB but not for 23andMe (Table 1). This set-up allowed us to investigate how different LD reference panels perform compared to the in-sample LD. In particular, we evaluated different statistics that could be used to assess fine-mapping quality when only reference LD is available. Finally, we utilized our results to fine-map 102 migraine risk loci to narrow down the putative causal variants behind the associations. We were able to get reliable fine-mapping results for 93 out of 102 regions and identified 7 variants with a high probability (>90%) of being causal and two missense variants, rs6330 in *NGF* and rs1133400 in *INPP5A,* with a probability > 50% of being causal.

110

112

Results

132 The genomic inflation factor (λ_{GC}) of the migraine meta-analysis was 1.38. There was a linear relationship between the association statistic and the LD-score

 (Supplementary Fig 1) indicating that the polygenic background of migraine was the main source of the genomic inflation. However, as the intercept from LDSC was elevated to 1.09 (s.e. 0.01) from its null value of 1.0, some inflation could also be due to confounding factors such as cryptic relatedness, population stratification or other model misspecification. Consequently, we further checked the LDSC intercepts for

 the individual studies: 1.03 (s.e. 0.01) for 23andMe, 1.00 (s.e. 0.01) for UKB and 140 1.10 (s.e. 0.01) for FinnGen. The higher intercept for FinnGen could be due to a 141 different GWAS analysis method (whole genome-regression by REGENIE²⁷ including related samples) compared to UKB and 23andMe (logistic regression excluding related samples). Estimated SNP-heritability was 11.49% (s.e. 0.47%) from LDSC when population prevalence was assumed to be 16%.

 We followed the locus definition of Hautakangas et al. (2022) and defined the LD-147 independent genome-wide significant (GWS; P < 5 × 10^{−8}) risk loci from the meta- analysis iteratively by choosing the variant with the smallest P-value as an index 149 variant and excluding all other GWS variants with LD $r^2 > 0.1$ to that index variant from further considerations until no GWS variants remained. Next, we formed a high 151 LD region around each index variant extending to the level of $r^2 > 0.6$, and merged regions that were closer than 250 kb. Lastly, all other GWS variants were included in their closest region, and the region boundaries were updated, and once again regions closer than 250 kb were merged (see further details in Methods). Based on this locus definition, we identified 122 LD-independent risk loci, of which 35 were new (Table 2), and 87 overlapped with the previously known risk loci (Fig 1, 157 Supplementary Table 1, Supplementary Figs 2-4)^{4,5,6,7,8,9,10,11,12,13,14}. We observed statistically significant heterogeneity (*P* < 0.05/122) in effect sizes between the study collections only for two lead variants, both of which resided in the previously known migraine loci (PRDM16 and near ZCCHC14)(Supplementary Table 1, Supplementary Fig 3). As external replication data of 34,807 cases and 193,475 162 controls, we meta-analyzed data from the Trøndelag Health Study (HUNT)²⁸ and IHGC16 migraine meta-analysis excluding the Finnish cohorts and the 23andMe

164 data⁹. Of the 35 lead variants of our new loci, 32 were consistent in direction ($P = 2.1$) \times 10⁻⁷, one-sided binomial test) and 17 replicated with P < 0.05 (one-sided test; Supplementary Table 2) in the replication data. When we meta-analyzed the discovery and the replication data, 28 out of the 35 novel loci remained GWS (Supplementary Table 2).

To define the fine-map regions, we merged together the risk loci that were closer

than 1.5 Mb. This resulted in 102 fine-map regions. To avoid problems due to

varying sample sizes across the variants, we included in fine-mapping only

autosomal SNPs that were available in all three cohorts. This criterion reduced the

number of common variants (MAF>0.05) per regions on average by 19%.

 Figure 1. A Manhattan plot of the inverse-variance weighted fixed effects migraine meta-analysis including 98,374 cases and 869,160 controls. X-axis presents the chromosomal location and y-axis the -log10(*P*-value). Known loci are highlighted in purple and new loci in green. Variants with posterior inclusion probability (PIP) > 0.9 and missense variants with PIP > 0.5 in high-quality fine-mapping regions are annotated.

184 Table 2. New 35 migraine risk loci identified from the meta-analysis of 98,374

185 migraine cases and 869,160 controls.

 RSID = reference SNP ID, GRCh37 = Genome Reference Consortium Human Build 37, s.e. = standard error. Alleles D and I refer to deletion and insertion, respectively.

Comparison of different LD panels in fine-mapping

 A common problem in meta-analyses is that the in-sample LD is not available, and use of reference LD may lead to biased results. Figure 2 demonstrates this problem at the locus around *TSPAN2* where fine-mapping using the in-sample LD disagrees strongly with the UKB reference LD but agrees well with a more accurate UKB-FG reference LD. This shows that, in our setting, fine-mapping based on the UKB-FG reference LD has a potential to yield reliable results but that we need some way to assess, for each region, whether the reference LD has provided reliable results. Therefore, we evaluated whether some statistics, either derived from the GWAS results or from the fine-mapping results, could flag the regions where the reference LD produced unreliable fine-mapping results compared to the in-sample LD. We did 201 this comparison in the 26 regions where the in-sample LD was available. As candidate statistics, we considered: (1) posterior expectation of the number of causal variants (PENC), and, from the top variant(s) of the credible sets, (2) maximum 204 pairwise r², (3) maximum marginal P-value, and (4) minimum INFO value. We used the maximum difference of the variant-specific posterior inclusion probabilities (maxΔ) between the reference LD and the in-sample LD to assess the quality of the refence LD results. A small maxΔ value (close to 0) indicates high quality (the reference LD produces similar results to the in-sample LD), and a large value (close 209 to 1) indicates low quality (the reference LD produces different results from the in-sample LD).

211 In general, both LD reference panels performed well in most of the 26 regions 212 available for this comparison, but, as expected²², the more accurate UKB-FG panel 213 performed clearly better than the UKB panel alone. For example, max∆ was above 214 0.1 only in 2/26 regions with the UKB-FG panel but in 8/26 regions with the UKB 215 panel (Fig 3a).

216

217 Figure 2. Fine-mapping a region near *TSPAN2* at chromosome 1 using three

218 different LD sources. a) Plot of the GWAS results with the chromosomal location on

219 x-axis and the strength of the association as -log10 *P*-values from the inverse-

220 variance weighted fixed-effect meta-analysis with 98,374 migraine cases and

221 869,160 controls on y-axis. Variants are colored based on the squared correlation

 $(222 \, \text{r}^2)$ to the two variants in the top configuration suggested by FINEMAP with the in-

223 sample LD. The suggested top configurations based on three LD panels are marked

224 by lines with the in-sample LD and the UKB-FG reference LD giving the same top

225 configuration and the UKB reference LD including three additional variants

226 (highlighted in green). Posterior inclusion probabilities (PIPs) for the variants based

227 on b) in-sample LD, c) UKB-FG reference LD and d) UKB reference LD.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.20.24307608;](https://doi.org/10.1101/2024.05.20.24307608) this version posted May 20, 2024. The copyright holder for this preprint

229

230 We then investigated how well the four different statistics could separate the regions 231 with low-quality fine-mapping results from those with high-quality results for the two 232 LD reference panels (Supplementary Fig 5). First, when PENC was used, both LD 233 reference panels performed similarly for the regions where FINEMAP suggested only 234 one or two causal variants (Supplementary Fig 5a). Those results were also close to 235 the in-sample results (maxΔ < 0.07). All low-quality regions (with maxΔ > 0.1) had 236 PENC > 2 with the UKB panel and PENC > 3 with the UKB-FG panel. Thus, we used 237 these PENC thresholds to define low-quality regions when the in-sample LD was not 238 available. We expect that these thresholds have a high sensitivity for low-quality

 results but will simultaneously exclude some of the regions that truly have many causal variants. The other three statistics are not able to distinguish the low-quality 241 regions as clearly as PENC (Supplementary Figs 5b-d). First, the maximum r^2 among the top configuration variants does not distinguish both of the low-quality regions with the UKB-FG panel (Supplementary Fig 5b). Additionally, neither the maximum *P* nor the minimum INFO within the top credible set variants separates well the low-quality regions from the good-quality regions (Supplementary Figs 5c,d). We conclude that PENC gives the best separation among the statistics investigated. Previously, PENC has been used to filter FINEMAP results in the schizophrenia fine-248 mapping study²⁴. Next, we evaluated how PENC classifies the 76 fine-map regions where only reference LD was available to us. The 76 grey points in Figure 3b show that the fine- map regions without the in-sample LD are typically having PENC < 2.5 and, with the UKB-FG LD, only 6 of the 76 regions have PENC > 3. Figure 3. a) Scatter plot comparing the maximum PIP differences (maxΔ) between the in-sample and reference LD for 26 fine-map regions. X-axis shows the UKB-FG reference LD and y-axis the UKB reference LD. b) Strip chart shows the posterior expected number of causal variants (PENC) from fine-mapping for the two LD reference panels for the 102 fine-map regions. Red dots indicate large differences 260 from the in-sample LD (max $\Delta > 0.1$), and grey color indicates regions for which only 261 reference LD is available and therefore max∆ is not known. Horizontal line shows PENC = 3 that we use as a threshold to define reliable results with the UKB-FG panel.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.20.24307608;](https://doi.org/10.1101/2024.05.20.24307608) this version posted May 20, 2024. The copyright holder for this preprint

265

267

268 Figure 4. Summary of the fine-mapping results across the 102 migraine risk regions.

269

 Overall, for a majority of the fine-map regions, FINEMAP suggested one (42%) or two (46%) causal variants (Supplementary Table 3, Fig 4.). The 102 fine-map regions together had 181 distinct signals when the signals were defined by the number of causal variants per region with the highest posterior probability. Among 274 the 76 regions without the in-sample LD, 6 had PENC above 3. We flagged these

 regions to be of low-quality, and their interpretation requires extra caution. The largest PENC observed was 5 and it occurred for two fine-map regions: *PRDM16* (index variant rs10218452) and *HOXB3* (index variant rs2555111). Of these, *HOXB3* region is flagged as low-quality because there is no in-sample LD available. The sizes of 95%-credible sets ranged from 1 to 2,787 variants, and 49 credible sets 280 had 10 variants or less. A very high PIP (\geq 0.9) was observed for 10 variants (Supplementary Table 4), of which seven were in the high-quality fine-map regions (Table 3). We conducted a look-up from Variant Effect Predictor (VEP) database for all credible sets to search for variants that could have an impact on the gene transcript. In total, 149 unique missense variants were found of which 3 had PIP > 0.5: rs6330 (PIP=0.59) in *NGF* located at chromosome 1, rs1133400 (PIP=0.93) in *INPP5A* located at chromosome 10 and rs28929474 (PIP=0.64) in *SERPINA1* located in a low-quality fine-map region at chromosome 14 (Table 3, Supplementary Table 5). Of these, rs6330 is a significant *cis*-eQTL for *NGF-AS1* expressed in atrial appendage of heart and rs28929474 for *IFI27L2* expressed in tibial artery and in left ventricle of heart in GTEx v.08 data. 291 NGF encodes protein nerve growth factor beta ($NGH\beta$) that is important in the development and survival of neurons, and involved in transmission of pain, temperature, and touch sensations via sensory neurons. It binds to two receptors, 294 NTRK1 encoded by NTRK1 and NGFR/p75^{NTR} encoded by NGFR. Of note, two additional missense variants among the credible sets, rs6339 (PIP= 0.48) and rs6336 (PIP=0.39), are located in *NTRK1* in a separate locus. The missense variant rs6330 shows association with multiple diseases of the musculoskeletal system and connective tissue including spinal stenosis, spondylosis, spondylopathies and hallux

 valgus in FinnGen R10 PheWAS scan, all to the opposite direction compared to the migraine risk (Supplementary Table 6).

 INPP5A encodes a membrane-associated type I inositol 1,4,5-trisphosphate 5- phosphate protein, which hydrolyzes Ins(1,4,5)P3 leading to the mobilization of intracellular calcium. It has a central role in various cellular signaling processes including neurotransmission, hormone secretion, cell proliferation and muscle contraction. *INPP5A* is highly expressed in Purkinje cells of cerebellum, and in mice studies its deletion have been shown to cause ataxia and cerebellar 307 degeneration^{29,30}. *SERPINA1* encodes an alpha-1 antitrypsin, a serine protease inhibitor protein, that belongs to the serpin superfamily. Its primary target is elastase, and other targets are plasmin and thrombin. Several mutations, including our high-PIP variant rs28929474C>T, in *SERPINA1* can cause an autosomal co-dominant genetic disorder alpha-1 antitrypsin (AAT) deficiency, which can lead to lung or liver disease due to reduced alpha-1 antitrypsin levels³¹. A missense variant rs28929474 is highly pleiotropic and shows associations to multiple disease categories in PheWAS of FinnGen R10 data including, for example, diseases of the respiratory system, diseases of the circulatory system, diseases of digestive system, pregnancy related diseases, diseases of the nervous system, and diseases of musculoskeletal system and connective tissue (Supplementary Tables 6-8).

 Five additional high-impact variants on protein function (1 stop gained, 2 start lost, and 2 splice acceptor variants) were among the credible sets, but only with modest PIPs below 0.01 (Supplementary Table 5), and another 5 variants with high-impact on something else than protein coding function (long non-coding RNA, antisense or nonsense mediated decay) with PIPs below 0.02.

341 Table 3. Variants with high (>0.9) posterior inclusion probability (PIP) and missense

343

 Due to the restriction of including in fine-mapping only the variants that are available in all three data sets, the original lead variant was missing in 17/102 fine-map regions (Supplementary Table 3b). In 14/17 of these regions, the original lead variant was represented by one of the top credible set variants (defined as being in LD with r2 > 0.1 in the UKB data). For the remaining 3 regions, the signal related to the original lead variant may be missing from the fine-mapping results, and we flagged these regions to be of low-quality. Among the fine-map regions for which the lead variant was included in the analysis, the lead variant was within the 95% credible sets in 83/85 fine-map regions and within the top configuration in 73/85 of the 353 regions. 354 Phenome-wide association scans for the credible set variants 356

357 We conducted three separate phenome-wide association studies (PheWAS) by 358 using data from FinnGen Data Freeze 10 including 429,209 individuals. First, by a

-
- Discussion

 Well over one hundred risk loci for migraine have been reported from GWAS, but the 382 causal variants and genes are still mostly unknown^{4,5,6,7,8,9,10,11,12,13,14}. Statistical fine-mapping of the GWAS results at the risk loci is a natural next step but reliable fine-

 mapping of large meta-analysis data has turned out to be very difficult. Our recent 385 migraine meta-analysis of 25 studies¹³ illustrated these difficulties as the accurate LD information was not available and the sample size varied considerably across variants. In this study, our goal was to provide reliable fine-mapping for migraine by creating a new migraine meta-analysis for which accurate LD information was available and sample size across variants was more stable. Despite the more stringent selection criteria, the effective sample size of our new meta-analysis (339,000) turned out to be comparable to that of the earlier meta-analysis (326,000).

 A key question in fine-mapping a GWAS meta-analysis is how to assess the reliability of the results. We were able to study this question by directly comparing results between accurate in-sample LD and approximate reference panel LD. We observed that the posterior expected number of causal variants (PENC) as reported by FINEMAP distinguished well the regions with high-quality fine-mapping results from those with low-quality results. We also observed that an appropriate PENC threshold depends on the quality of the reference panel. In our case, we were able to use an upper limit of 3.0 for PENC. While this upper limit restricts our ability to fine- map the migraine risk regions that truly have more than 3 causal signals, we expect that the proportion of such regions is small, as only 3/26 (12%) of the migraine loci with the in-sample LD had PENC over 3 in our analysis.

 Here, we performed the first systematic fine-mapping of a migraine meta-analysis and provided high-quality fine-mapping results for 91% of the migraine risk regions identified by the meta-analysis. Our high-quality results highlight two missense

 variants with high PIPs: rs6330 (PIP=0.59) in *NGF* and rs1133400 (PIP=0.93) in *INPP5A.*

410 The variant rs6330 is only in weak LD ($r2 = 0.04$) with the lead variant ($rs12134493$) of its locus and was identified as a secondary signal in our fine-mapping. A recent study¹⁴ has also reported that the migraine association of rs6330 remained statistically significant in a conditional analysis after adjusting for the stronger signal (rs2078371) within the same risk locus. *NGF* has been reported to be highly 415 expressed in hippocampus and cortex^{41,42} although according to the GTEx v8 data, *NGF* does not show statistically significant expression in any brain tissue but shows high expression in multiple other tissues, including, for example, ovary, tibial nerve, arteries, visceral adipose, and heart. NGF levels have been reported to be elevated in cerebrospinal fluid in chronic migraine patients compared to controls⁴³, and decreased in blood serum of episodic migraine patients compared to controls and 421 chronic migraine patients⁴⁴. In addition, we observed two additional missense variants with considerable PIPs, rs6339 (PIP=0.48) and rs6336 (PIP=0.39), located in *NTRK1* which encodes one of the two receptors for NGF. NGF and its receptors have a central role in the pain perception, and elevated NGF levels have been 425 observed also in many other chronic pain conditions, such as osteoarthritis and low 426 back pain^{45,46,47}. Multiple antibodies of NGF or small molecular inhibitors of the NGF 427 receptors have been developed and tested in clinical studies to treat chronic pain 428 conditions, including low back pain and osteoarthritis^{48,49,50,51,52}. Even though some candidate drugs have shown potential benefit relating to pain relief, an increased risk of progressive osteoarthritis has been observed in a small group of the treated 431 patients⁵², and therefore none of the drugs have yet received FDA approval. Currently, other type of drug classes (p75 neurotrophin receptor fusion protein, LEVI-

[\(ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05618782) ID: NCT05618782) and anti-NGF PEGylated Fab' antibody⁵³), are being developed and in pre-clinical or clinical testing. In adults, after pain stimuli, NGF activates overexpression of other neuronal molecules, including calcitonin 436 gene-related peptide (CGRP) and substance P^{52} . CGRP is involved in migraine pain, and several effective monoclonal antibodies targeting either CGRP or its receptors 438 have been developed to treat migraine $54,55,56$. 439 Gene *INPP5A* is highly expressed in Purkinje cells of cerebellum⁵⁷ and involved in multiple cellular signaling processes including neurotransmission, hormone secretion, cell proliferation and muscle contraction through its role in the pathway regulating intracellular calcium levels. The missense variant rs1133400 is in modest LD (r2 = 0.36) with the lead variant of the locus (rs200314499) that was filtered out from fine-mapping due to QC. For this locus, FINEMAP suggested two causal variants (PENC = 1.65)*.* PheWAS showed no other significant associations with this

missense variant.

 Another important finding is in the *PHACTR1* locus, which is one of the strongest known migraine risk loci. There our fine-mapping suggested one causal variant (PENC = 1.29), with the lead variant rs9349379 being a clear candidate for being causal with PIP of 1.00. In our FinnGen PheWAS, we detected also strong associations between the variant and, for example, major coronary disease events (1.453) $(P = 8.22 \times 10^{-52})$, ischemic heart disease $(P = 1.18 \times 10^{-38})$ and angina pectoris (*P* $454 = 7.71 \times 10^{-26}$, all to the opposite directions compared to migraine risk. Because of these well-known associations with multiple vascular diseases, this locus has been 456 previously studied in detail but with contradicting results. Gupta et al. $(2017)^{32}$ reported that rs9349379 regulates upstream gene *EDN1*, whereas Wang et al.

458 (2018)³³ reported that they failed to replicate this endothelial rs9349379-EDN1 eQTL, but instead showed that rs9349379 regulates the closest gene *PHACTR1,* confirming previous vascular rs9349379-PHACTR1 eQTLs. Further, Rubin et al (2022)58 observed that a loss of *PHACTR1* gene does not seem to have any effect 462 on the endothelial or smooth muscle cells of the transgenic mice, and suggested that *PHACTR1* has no contribution to pathological vascular phenotype in mice through cells involved in vascular physiology. Our fine-mapping has provided strong evidence that the lead variant rs9349379 is causal for migraine, but given that the variant is intronic, our fine-mapping results alone do not provide direct evidence through which gene or mechanism this association affects the disease risk. Our study has some limitations. First, since reliable fine-mapping requires that we exclude variants that are not present in all three component studies of our meta- analysis, it is possible that we exclude also some of the true causal variants. This is a potential problem especially when some of the top variants of the fine-map region have been filtered out from fine-mapping. To identify the regions that are likely to be affected by this problem, we studied the LD patterns between the fine-mapped 475 variants and those top variants from the fine-map regions that were not included in the fine-mapping analysis. For most (14/17) regions where the top variants were missing from fine-mapping, the signal of the top variant was at least partly represented by another variant in LD with the top variant. Additionally, since very rare variants were not included in our analysis, we miss the true causal variants that are rare. Since our variant set is not comprehensive, we must keep in mind that also variants that have a very high probability of being causal in our analysis may still

have such variants in high LD that were not included in our analysis. A valid

 calibration of the PIPs would require that all potential causal variants were included in the analysis. In practice, for common variants, this would require comprehensively imputed data sets with no missing variants in any of the meta-analyzed studies, and, for rare variants, availability of high coverage sequencing data. Currently, we do not yet have such resources available in typical GWAS meta-analyses of common diseases such as migraine.

 Another limitation of our study relates to the phenotype definitions of different substudies. First, both the UKB and 23andMe GWAS are based on self-reported migraine status, and therefore some other conditions, such as tension headache, may have been wrongly reported as migraine for some cases. Second, the FinnGen GWAS is based on triptan purchase data, which may represent a specific subset of migraine patients. Triptans are not suitable for all migraineurs and, especially, they are contraindicated in patients with cardiovascular diseases. Overrepresentation of migraineurs without any cardiovascular diseases could lead some FinnGen PheWAS associations where migraine risk alleles seem to have protective effect on cardiovascular phenotypes. Observational studies have reported that both migraine 499 and cardiovascular disease risk in women are positively associated⁵⁹.

 To conclude, we performed a migraine GWAS meta-analysis with 98,375 migraine cases and 869,159 controls and identified 122 risk loci of which 35 were new. We followed up the meta-analysis by the first systematic fine-mapping analysis of migraine risk loci and identified 7 variants with a high probability of being causal. In addition to providing new information about genetic risk of migraine, we also proposed how one could, in general, evaluate whether the fine-mapping results of each risk loci seem reliable based only on the output from the fine-mapping software

- FINEMAP. While a definitive fine-mapping analyses will require more comprehensive
- data than are currently available for the GWAS meta-analyses of common diseases,
- our study shows how reliable and novel fine-mapping results can be extracted
- already from the currently available data sets by a suitable analysis approach.

-
- Data
-
- We performed a new migraine meta-analysis by combining summary statistics from
- three migraine GWAS: UK Biobank (N= 341,050, 10,881 cases and 330,169

controls), 23andMe (N=283,985, 53,109 cases and 230,876 controls), and FinnGen

R8 (N= 342,499, 34,385 cases and 308,114 controls). By meta-analyzing the three

studies, the total sample size was 967,534 including 98,375 migraine cases and

869,159 controls.

 UK Biobank: The UK Biobank project is a population-based prospective cohort study that consists of over 500,000 participants aged 40-69 at recruitment collected from several regions across the United Kingdom. The participants completed questionnaires and attended interviews and clinal examinations by a trained staff 527 member. A detailed description of UK Biobank is provided elsewhere⁶⁰, and detailed genotyping, quality control and imputation procedures are described at the UK Biobank website (https://www.ukbiobank.ac.uk/). We used the migraine GWAS data described in¹³ with self-reported migraine as the phenotype. UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (MREC) and informed consent has been obtained from all participants.

23andMe: 23andMe migraine GWAS was performed by a personal genomics

company 23andMe, Inc. (https://www.23andme.com/) and detailed description of the

536 \ldots migraine GWAS is provided elsewhere⁸. All participants have provided informed

 consent and filled an online survey according to 23andMe's human subjects protocol, which was reviewed and approved by Ethical & Independent Review Services, a private institutional review board. Briefly, migraine cases were assessed from the participants that had reported migraine or answered "Yes" to any of the questions related to migraine, and controls from participants that did not report having migraine or answered "No" to all of the questions related to migraine, excluding participants with discordant answers.

 FinnGen: FinnGen [\(https://www.finngen.fi/en\)](https://www.finngen.fi/en) is a large biobank study that has collected and genotyped 500,000 Finns and combined these data with longitudinal registry data including The National Hospital Discharge Registry, Causes of Death Registry and medication reimbursement registries, all of these linked by unique national personal identification codes. FinnGen includes prospective and retrospective epidemiological and disease-based cohorts and hospital biobank 551 samples. A detailed description of FinnGen is provided in⁶¹. We used the 8th Data Freeze for the migraine GWAS. The migraine cases were defined as the individuals who had at least one triptan purchase and the remaining individuals without any triptan purchases were defined as controls from the social insurance institution of Finland (KELA) registry including medication reimbursement and drug purchases (https://r8.risteys.finngen.fi/phenocode/MIGRAINE_TRIPTAN). FinnGen participants provided informed consent under the Finnish Biobank Act. Older cohorts with study-specific consents were transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The

- Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa
- (HUS) approved the FinnGen study protocol (Nr HUS/990/2017).
- The FinnGen study is approved by Finnish Institute for Health and Welfare (permit
- numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
- THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
- THL/1524/5.05.00/2020), Digital and population data service agency (permit
- numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social
- Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018,
- KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019,
- KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers
- THL/2364/14.02/2020, THL/4055/14.06.00/2020,,THL/3433/14.06.00/2020,
- THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020,
- THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021,
- THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020,
- THL/2658/14.06.00/2021, THL/4235/14.06.00/2021 and Statistics Finland (permit
- numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20)
- TK/1735/07.03.00/2021).
- The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen
- Data Freeze 8 include: THL Biobank BB2017_55, BB2017_111, BB2018_19,
- BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26,
- BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank
- HUS/359/2017, Auria Biobank AB17-5154 and amendment #1 (August 17 2020),
- AB20-5926 and amendment #1 (April 23 2020), Biobank Borealis of Northern
- Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 §
- /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 &

 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

 We have access to the complete in-sample LD information for the UK Biobank and FinnGen samples via the individual-level genotype data. Additionally, we have access to the in-sample LD-matrices in 23andMe data for 26 of our fine-map regions. Thus, for the 26 fine-map regions, we are able to do a high-quality fine-mapping based on the in-sample LD while, for the remaining 76 regions, we need to apply an LD reference panel that does not perfectly match the LD information corresponding to our GWAS summary statistics. To assess the effect of the LD reference panel, we formed two reference panels from the available LD information: one including data only from the UK Biobank (UKB), and the other combining the LD matrices from UK Biobank and FinnGen (UKB-FG), as explained in section "Fine-mapping".

Genetic association analyses

The UK Biobank and 23andMe GWAS had been conducted by logistic regression on

603 migraine (using PLINK2 or custom software of the 23andMe Research Team,

 respectively), and the FinnGen GWAS by a whole-genome regression model for a binary trait with REGENIE²⁷.

 All the samples were of European descent. Related individuals had been excluded by using a kinship value threshold of 0.0442 computed by KING 63 from UK Biobank, and by using a minimal expected amount of sharing between first cousins from a segmental identity-by descent algorithm from 23andMe. For the FinnGen GWAS

 analysis, REGENIE accounted for the genetic relatedness by default, and therefore no relatedness exclusions were applied.

 We excluded multi-allelic variants, and variants with minor allele frequency (MAF) < 0.01 , IMPUTE2 info or MACH r^2 < 0.6, and when available, missingness > 0.05 and Hardy-Weinberg equilibrium (HWE) *P* < 1 × 10−6 from each study. Consequently, we are only considering biallelic common variants in this work. We recoded indels as insertions (I) and deletions (D). We mapped the FinnGen GWAS summary statistics 617 positions from hg38 to hg37 by UCSC LiftOver 64 . We excluded the SNPs with an effect allele frequency (EAF) discrepancy of >0.30 and indels with an EAF discrepancy of >0.20 compared to UK Biobank from each study following Hautakangas et al. 2022. We conducted an inverse-variance weighted fixed-effects meta-analysis to combine 622 the three studies by GWAMA with 11,316,120 variants, of which 7,062,924 variants were available in all three studies. Genetic correlation and SNP-heritability using LD Score regression We estimated genetic correlations between the three GWAS and SNP-heritability 628 from the migraine meta-analysis by LD Score regression $v1.0.0^{66,25}$ with precomputed 1000 Genomes European LD Scores [\(https://data.broadinstitute.org/alkesgroup/LDSCORE/\)](https://data.broadinstitute.org/alkesgroup/LDSCORE/) limiting the analysis to the HapMap3 SNPs. We used munge-tool to reformat and perform additional quality control for all GWAS summary statistics prior to the genetic correlation estimation. 633 We obtained a liability scale SNP-heritability estimate⁶⁷ by using a population prevalence of 16% for migraine.

Locus definition

 We followed the locus definition of Hautakangas et al. (2022) and defined an LD-639 independent genome-wide significant (GWS, $P < 5 \times 10^{-8}$) risk locus from the meta- analysis by using the UKB LD. Iteratively, we chose the variant with the smallest *P*-641 value as the index variant and excluded all variants that had $r^2 \ge 0.1$ with the index 642 variant, until no variant had $P < 5 \times 10^{-8}$. Next, we formed high LD regions around 643 each index variant based on the combined UKB-FG LD and r^2 threshold of 0.6. The start of the high LD region was the smallest position, and the end of the region was 645 the largest position where any variant had $r^2 > 0.6$ with the index variant. Next, we 646 formed the loci by adding $+250$ kb around the high LD region and merged the overlapping regions. Further, we iteratively added all other GWS variants to their closest loci, and updated the loci boundaries if any of the variants added were outside the existing locus boundaries. Again, the overlapping loci were merged. We named each locus by the lead variant, i.e., the variant with the smallest *P*-value of the locus.

Replication in HUNT All-in Headache and IHGC16

 To replicate our new loci, we used two independent data sets with no overlaps with 656 our GWAS data: HUNT All-in Headache²⁸ (N=40,224, 7,801 cases, 32,423 controls) 657 and IHGC16 migraine meta-analysis excluding 23andMe and the Finnish cohorts (N $658 = 189,000$, $27,006$ migraine cases and 161,994 controls). The meta-analysis of the replication data thus contained N=229,224 samples (34,807 cases and 194,417

 controls). We used a one-sided *P*-value threshold of 0.05 to denote a replication and assessed consistency of the effect directions by a sign test. We also reported the two-sided *P*-value of a combined analysis of our discovery and replication results to determine which of the new loci remained GWS after observing the replication data. Fine-mapping For fine-mapping, we first merged loci that were closer than 1.5 Mb leading to 102 fine-map regions. We performed fine-mapping for each fine-map region with 669 FINEMAP v1.4^{19,22}. FINEMAP is a Bayesian method that uses summary statistics from a GWAS together with LD information to infer which variants are most likely causal within the genomic region. We used the default prior parameters and set the maximum number of causal variants to 10. We estimated the in-sample LD correlations for the individual GWAS cohorts by using LDStore2²². We combined the in-sample LD correlations for the meta-analysis data set by combining the study-specific LD matrices by weighting each matrix in proportion to its effective sample size as follows: **R** = $(M_1 R_1 + ... + M_C R_C) / M$, (F1) 680 where **R**_i is the LD correlation matrix of study i, $M_i = 4N_i p_i (1-p_i)$ is the effective 681 sample size of study i, with N_i being the total sample size (i.e., the sum of cases and 682 controls) and p_i being the proportion of cases in study i, and M = $M_1 + ... + M_c$ is the sum of the effective sample sizes.

 For the UK Biobank reference LD (UKB-LD), we used the in-sample LD estimated from the individuals included in the UKB GWAS.

 For the combined UKB-FG LD reference panel, we combined the UKB and FG in- sample LD matrices by weighting FG in proportion to its effective sample size, and UKB in proportion to the combined UKB+23andMe effective sample size using the above formula (F1).

-
- LD reference panel sensitivity analyses
-

We compared the performance of different LD refence panels (UKB LD, UKB-FG LD

and in-sample LD) on the FINEMAP results for the 26 fine-map regions for which the

in-sample LD was available. We used the maximum difference between the posterior

inclusion probabilities (PIPs) from different panels (maxΔ) to compare the

performance of the three LD panels.

In addition, we examined the following candidate statistics which could be used for

separating the fine-map regions for which the fine-mapping with the reference LD

performs poorly when compared to the use of the in-sample LD: 1) the posterior

- expectation of the number of causal variants (PENC), and, from the top variant(s) of
- 703 the credible set(s) determined by FINEMAP, 2) the maximum pairwise r^2 , 3) the
- maximum marginal *P*-value from the meta-analysis, or 4) the minimum INFO value.
-

Variant annotation by VEP and eQTL mapping

FINEMAP reports 95%-credible sets (CS). We searched for coding variants among

the CS from the Ensembl VEP

- [\(http://grch37.ensembl.org/Homo_sapiens/Tools/VEP\)](http://grch37.ensembl.org/Homo_sapiens/Tools/VEP) database by using a default of
- 5 kb window around the index variant.
-
- For the follow-up analyses, we formed a functional variant group among the CS
- variants by including the variants that were predicted by VEP to have a moderate or
- high impact on the transcript
- [\(https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html\)](https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html). This
- includes transcript ablation, splice acceptor or donor variants, stop gained, frameshift
- variant, stop lost, start lost, transcript amplification, inframe insertion or deletion, and
- missense variant.
- We mapped the functional variant set, and also another set including all variants with
- 721 PIP > 0.1 (highPIP), to significant eQTLs of the 49 tissues from GTEx v.8
- (https://gtexportal.org/home/).
-

Phenome-wide association scans

 We performed three phenome-wide association scans (PheWAS). First, we scanned 727 all 181 candidate variants of the risk loci (top variants of the credible sets) among the 2,399 FinnGen Data Freeze 10 (R10) GWAS endpoints (excluding 9 migraine endpoints) at significance level 1 \times 10⁻⁵. Second, we scanned all variants annotated as functional variants with a moderate to high impact on protein function by VEP among neurological and cardiovascular endpoints from FinnGen R10, including the FinnGen endpoint categories Neurological endpoints, VI Diseases of the nervous 733 system (G6), and IX Diseases of the circulatory system (I9) with at significance 734 level 1 × 10⁻⁴.

- Third, we scanned all variants with PIP > 0.1 among the same FinnGen neurological
- and cardiovascular endpoints at significance level 1 \times 10⁻⁴.
- Results can be browsed from PheWAS app
- https://hhautakangas.github.io/phewas_migraine_tables.html.
-

Data availability

- The access to the UK biobank data can be applied through
- <https://www.ukbiobank.ac.uk/>
- The GWAS summary statistics for FinnGen R8 are publicly available through
- [https://www.finngen.fi/en/access_results.](https://www.finngen.fi/en/access_results) The Finnish biobank data can be accessed
- 745 through the Fingenious® services [\(https://site.fingenious.fi/en/\)](https://site.fingenious.fi/en/) managed by FINBB.
- Finnish Health register data can be applied from Findata [\(https://findata.fi/en/data/\)](https://findata.fi/en/data/).
- The GWAS summary statistics for the 23andMe data set will be made available
- through 23andMe to qualified researchers under an agreement with 23andMe that
- protects the privacy of the 23andMe participants. Please visit
- <https://research.23andme.com/collaborate/#publication> for more information and to
- apply to access the data.
-
- Acknowledgements
-
- We would like to thank the research participants and employees of 23andMe, Inc. for
- making this work possible. We thank all the study participants, employees, and
- investigators of FinnGen and the UK Biobank for their contribution to this research.
- This research has been conducted using the UK Biobank Resource under
- Application Number 22627. This work was supported by grants no. 336825, 338507,

 352795 from the Research Council of Finland to M.P., by Sigrid Jusélius foundation (M.P. and A.P.) and by the Doctoral School of University of Helsinki (H.H.). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja- opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-774 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty- medicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperative - FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

- 811 Lehtimäki⁴³, Davor Lessel³⁹, Lannie Ligthart⁸, Sigurdur H Magnusson⁷, Rainer
- 812 Malik¹⁹, Bertram Müller-Myhsok⁴⁴, Carrie Northover⁴⁵, Dale R Nyholt⁴⁶, Jes Olesen¹²,
- 813 Aarno Palotie^{26,47}, Priit Palta²⁶, Linda M Pedersen⁴⁸, Nancy Pedersen⁴⁹, Matti
- 814 Pirinen^{26,50,51}, Danielle Posthuma⁵², Patricia Pozo-Rosich⁵³, Alice Pressman⁵⁴, Olli
- 815 Raitakari^{55,56,57}, Caroline Ran⁵, Gudrun R Sigurdardottir⁶, Hreinn Stefansson⁷, Kari
- 816 Stefansson⁷, Olafur A Sveinsson³⁰, Gisela M Terwindt¹⁸, Thorgeir E Thorgeirsson⁷,
- 817 Arn MJM van den Maagdenberg^{18,28}, Cornelia van Duijn⁵⁸, Maija Wessman^{26,29},
- 818 Bendik S Winsvold^{9,48,59}, John-Anker Zwart^{9,10,48}
- 819

820 ¹ Analytical and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital 821 and Harvard Medical School, Boston, Massachusetts, USA; ² Program in Medical and Population 822 Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; ³Stanley Center for 823 Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; 824 ⁴Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; ⁵Department of 825 Neuroscience, Karolinska Institutet, Stockholm, Sweden; ⁶Neurology private practice, Laeknasetrid, 826 Reykjavik, Iceland; 7deCODE genetics/Amgen Inc., Reykjavik, Iceland; ⁸Netherlands Twin Register, 827 Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands; $9K.G.$ Jebsen 828 Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and 829 Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; ¹⁰ Institute of 830 Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ¹¹Research and 831 Communication Unit for Musculoskeletal Health, Department of Research, Innovation and Education, 832 Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway; ¹²Danish Headache Center, 833 Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark; ¹³Department of 834 Medicine, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, 835 USA; ¹⁴Harvard Medical School, Boston, Massachusetts, USA; ¹⁵Department of Genetics, Spain 836 Centre for Biomedical Network Research on Rare Diseases, University of Barcelona, Barcelona, 837 Spain; ¹⁶ Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain; 838 ¹⁷University of Bristol/Medical Research Council Integrative Epidemiology Unit, University of Bristol, 839 Bristol, UK; ¹⁸Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands; 840 ¹⁹ Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany; 841 ²⁰Munich Cluster for Systems Neurology, Munich, Germany; ²¹ Estonian Biobank Registry, the 842 Estonian Genome Center, University of Tartu, Tartu, Estonia; ²²Department of Neurology, Klinikum 843 Passau, Passau, Germany; ²³Department of Neurology and Epileptology, Hertie Institute for Clinical

844 Brain Research, University of Tuebingen, Tuebingen, Germany; ²⁴GSK Inc., Cambridge, 845 Massachusetts, USA; ²⁵Centre for Genomics and Personalised Health, Queensland University of 846 Technology, Brisbane, Queensland, Australia; ²⁶Institute for Molecular Medicine Finland, Helsinki 847 Institute of Life Science, University of Helsinki, Helsinki, Finland; ²⁷Novo Nordic Foundation Center for 848 Protein Research, Copenhagen University, Copenhagen, Denmark; ²⁸Department of Human 849 Genetics, Leiden University Medical Centre, Leiden, the Netherlands; ²⁹ Folkhälsan Research Center, 850 Helsinki, Finland; ³⁰Landspitali University Hospital, Reykiavik, Iceland; ³¹Department of Epidemiology, 851 Erasmus University Medical Center, Rotterdam, the Netherlands; ³²Department of Epidemiology and 852 Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College 853 London, London, UK; ³³Center for Life Course Health Research, Faculty of Medicine, University of 854 Oulu, Oulu, Finland; ³⁴Unit of Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland; 855 ³⁵Department of Life Sciences, College of Health and Life Sciences, Brunel University London, 856 London, UK; ³⁶Research and Communication Unit for Musculoskeletal Health, Department of 857 Research, Innovation and Education, Division of Clinical Neuroscience, Akershus University Hospital 858 and University of Oslo, Oslo, Norway; ³⁷Department of General Practice, Institute of Health and 859 Society, University of Oslo, Oslo, Norway; ³⁸Department of Neurology, Akershus University Hospital, 860 Lørenskog, Norway; ³⁹ Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 861 Hamburg, Germany; ⁴⁰ Psychiatric and Neurodevelopmental Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; ⁴¹Institute of Public Health, Charité – 863 Universitätsmedizin, Berlin; ⁴² Laboratory of Epidemiology and Population Sciences, Intramural 864 Research Program, National Institute on Aging, Bethesda, Maryland, USA; ⁴³Department of Clinical 865 Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center - Tampere, Faculty of 866 Medicine and Health Technology, Tampere University, Tampere, Finland; 44Max Planck Institute of 867 Psychiatry, Munich, Germany; ⁴⁵23&Me Inc., Mountain View, California, USA; ⁴⁶School of Biomedical 868 Sciences, Faculty of Health, Centre for Genomics and Personalised Health, Centre for Data Science, 869 Queensland University of Technology, Brisbane, Queensland, Australia; ⁴⁷University of Helsinki, 870 Helsinki, Finland; ⁴⁸Department of Research, Innovation and Education, Division of Clinical 871 Neuroscience, Oslo University Hospital, Oslo, Norway; ⁴⁹Department of Medical Epidemiology and 872 Biostatistics, Karolinska Institutet, Stockholm, Sweden; ⁵⁰Department of Mathematics and Statistics, 873 University of Helsinki, Helsinki, Finland; ⁵¹Department of Public Health, University of Helsinki, Helsinki, 874 Finland; ⁵²Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive 875 Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands; 876 ⁵³Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain; 877 ⁵⁴Sutter Health, Sacramento, California, USA; ⁵⁵Centre for Population Health Research, University of 878 Turku, Turku University Hospital, Turku, Finland; ⁵⁶Research Centre of Applied and Preventive 879 Cardiovascular Medicine, University of Turku, Turku, Finland; ⁵⁷Department of Clinical Physiology and 880 Nuclear Medicine, Turku University Hospital, Turku, Finland; ⁵⁸Department of Epidemiology, Erasmus 881 University Medical Centre, Rotterdam, the Netherlands; ⁵⁹Department of Neurology, Oslo University 882 Hospital, Oslo, Norway

885 HUNT All-in Headache

892

893 1Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, 894 Oslo, Norway, ² Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, 895 ³K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of 896 Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 897 Trondheim, Norway, ⁴Department of Research and Innovation, Division of Clinical Neuroscience, Oslo 898 University Hospital, Oslo, Norway, ⁵K. G. Jebsen Center for Genetic Epidemiology, Department of 899 Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of 900 Science and Technology (NTNU), Trondheim, Norway, ⁶Department of Neurology, Oslo University 901 Hospital, Oslo, Norway, ⁷Department of Internal Medicine, Division of Cardiovascular Medicine, 902 University of Michigan, Ann Arbor, MI, 48109, USA, ⁸Department of Neuromedicine and Movement 903 Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology 904 (NTNU), Trondheim, Norway, ⁹Department of Neurology and Clinical Neurophysiology, St. Olavs 905 Hospital, Trondheim University Hospital, Trondheim, Norway, ¹⁰Department of General Practice, 906 University of Oslo, Oslo, Norway, ¹¹Department of Neurology, Akershus University Hospital, 907 Lørenskog, Norway, ¹²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, 908 Denmark, ¹³HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine 909 and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 910 ¹⁴Department of Research, Innovation and Education, St. Olavs Hospital, Trondheim University 911 Hospital, Trondheim, Norway, ¹⁵Department of Neurology, Oslo University Hospital, Oslo, Norway, 912 ¹⁶Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, 913 48109, USA, ¹⁷Norwegian Advisory Unit on Headaches, St. Olavs Hospital, Trondheim University 914 Hospital, Trondheim, Norway, ¹⁸Department of Clinical and Molecular Medicine, Norwegian University 915 of Science and Technology (NTNU), Trondheim, Norway, ¹⁹ BioCore - Bioinformatics Core Facility, 916 Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ²⁰Clinic of Laboratory 917 Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ²¹Research and 918 Communication Unit for Musculoskeletal Health (FORMI), Department of Research and Innovation, 919 Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway, ²²Department of

- Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA,
- 921 ²³ Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
-
- Competing interests
-
- 925 A.P. is the Scientific Director of the public-private partnership project FinnGen that
- has 12 industry partners that provide funding for the FinnGen project.
- Other authors report no conflicts of interests.
-

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.20.24307608;](https://doi.org/10.1101/2024.05.20.24307608) this version posted May 20, 2024. The copyright holder for this preprint

References:

932 1. (IHS), H.C.C.o.t.I.H.S. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia* **38**, 1-211 (2018). 2. Vos, T. *et al.* Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* **396**, 1204-1222 (2020). 938 3. Gervil, M., Ulrich, V., Kaprio, J., Olesen, J. & Russell, M.B. The relative role of genetic and environmental factors in migraine without aura. *Neurology* **53**, 995-999 (1999). 4. Anttila, V. *et al.* Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. *Nature Genetics* **42**, 869-873 (2010). 5. Chasman, D.I. *et al.* Genome-wide association study reveals three susceptibility loci for common migraine in the general population. *Nature Genetics* **43**, 695-U116 (2011). 6. Freilinger, T. *et al.* Genome-wide association analysis identifies susceptibility loci for migraine without aura. *Nature Genetics* **44**, 777-782 (2012). 7. Anttila, V. *et al.* Genome-wide meta-analysis identifies new susceptibility loci for migraine. *Nature Genetics* **45**, 912-U255 (2013). 8. Pickrell, J.K. *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nature Genetics* **48**, 709-717 (2016). 9. Gormley, P. *et al.* Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. *Nature Genetics* **48**, 856-866 (2016). 10. Chen, S.-P. *et al.* Genome-wide association study identifies novel susceptibility loci for migraine in Han Chinese resided in Taiwan. *Cephalalgia* **38**, 466-475 (2018). 11. Chang, X. *et al.* Common variants at 5q33.1 predispose to migraine in African- American children. *Journal of Medical Genetics* **55**, 831 (2018). 12. Choquet, H. *et al.* New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis. *Communications Biology* **4**, 864 (2021). 13. Hautakangas, H. *et al.* Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. *Nature Genetics* **54**, 152-160 (2022). 14. Bjornsdottir, G. *et al.* Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura. *Nature Genetics* **55**, 1843-1853 (2023). 15. Finucane, H.K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nature Genetics* **50**, 621-629 (2018). 16. Schaid, D.J., Chen, W. & Larson, N.B. From genome-wide associations to candidate causal variants by statistical fine-mapping. *Nature Reviews Genetics* **19**, 491-504 (2018). 17. Kichaev, G. *et al.* Integrating functional data to prioritize causal variants in statistical fine-mapping studies. *PLoS Genet* **10**, e1004722 (2014). 971 18. Hormozdiari, F., Kostem, E., Kang, E.Y., Pasaniuc, B. & Eskin, E. Identifying causal variants at loci with multiple signals of association. *Genetics* **198**, 497-508 (2014). 19. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493-1501 (2016).

